What does this research mean for the field?

Metabolic dysfunction-associated steatotic liver disease (MASLD) is driven by hepatic lipid metabolic reprogramming and the accumulation of bioactive lipid species that cause metabolic stress and cellular damage, rather than passive triglyceride accumulation. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review the mechanisms through which altered hepatic lipid metabolism and bioactive lipid signaling drive disease progression in metabolic dysfunction-associated steatotic liver disease and assess emerging therapeutic avenues.

September 3, 2026International Journal of Molecular SciencesOpen Access

Lipid Metabolic Reprogramming and Bioactive Lipid Signaling in MASLD: Molecular Mechanisms, Pathogenesis and Therapeutic Opportunities

View Full Paper

Ask AI

Bookmark

Authors

TÁTatjána ÁbelSemmelweis University ÉCÉva Csobod CsajbóknéSemmelweis University

Discussion

Member takes

Implication

Review reveals how bioactive lipid signaling drives cellular injury and fibrosis in metabolic dysfunction-associated steatotic liver disease, highlighting precision targets for molecular therapy.

Key Points

To review the mechanisms through which altered hepatic lipid metabolism and bioactive lipid signaling drive disease progression in metabolic dysfunction-associated steatotic liver disease and assess emerging therapeutic avenues.
Narrative synthesis of molecular and clinical evidence addressing fatty acid uptake, lipogenesis, β-oxidation, and lipid export dysregulation in liver tissue.
Evaluation of lipidomic profiling data and translational targets spanning nuclear receptors, ceramide synthesis, inflammatory cascades, and fibrogenesis.
Bioactive lipids, such as ceramides, diacylglycerols, oxidized phospholipids, and free cholesterol, act as metabolic toxins that trigger endoplasmic reticulum stress and disrupt mitochondrial homeostasis.
Downstream activation of inflammatory pathways—including PKC, JNK, MAPK, NF-κB, and the NLRP3 inflammasome—leads to hepatocyte cell death and progressive fibrogenesis.
Hepatic lipid species composition and subcellular localization show stronger correlation with disease severity than simple total triglyceride accumulation, identifying key avenues for precision endotyping.

Cite This Study

Ábel et al. (2026) studied this question.

synapsesocial.com/papers/6a993511636c6408cfa7cebc https://doi.org/10.3390/ijms27177805

View Full Paper

Ask AI

Bookmark

Implication

Review reveals how bioactive lipid signaling drives cellular injury and fibrosis in metabolic dysfunction-associated steatotic liver disease, highlighting precision targets for molecular therapy.

Lipid Metabolic Reprogramming and Bioactive Lipid Signaling in MASLD: Molecular Mechanisms, Pathogenesis and Therapeutic Opportunities

Discussion

Member takes

Implication

Key Points

Cite This Study

Lipid Metabolic Reprogramming and Bioactive Lipid Signaling in MASLD: Molecular Mechanisms, Pathogenesis and Therapeutic Opportunities

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider